GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » ROA %

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) ROA % : -22.40% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Chongqing Genrix Biopharmaceutical Co's annualized Net Income for the quarter that ended in Sep. 2024 was ¥-737.64 Mil. Chongqing Genrix Biopharmaceutical Co's average Total Assets over the quarter that ended in Sep. 2024 was ¥3,293.57 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 was -22.40%.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's ROA % or its related term are showing as below:

SHSE:688443' s ROA % Range Over the Past 10 Years
Min: -77.53   Med: -42.92   Max: -22.44
Current: -22.44

During the past 5 years, Chongqing Genrix Biopharmaceutical Co's highest ROA % was -22.44%. The lowest was -77.53%. And the median was -42.92%.

SHSE:688443's ROA % is ranked better than
62.34% of 1503 companies
in the Biotechnology industry
Industry Median: -35.81 vs SHSE:688443: -22.44

Chongqing Genrix Biopharmaceutical Co ROA % Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co ROA % Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-34.12 -77.53 -42.92 -58.67 -35.17

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.35 -25.44 -18.59 -23.46 -22.40

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's ROA %

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's ROA % distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's ROA % falls into.



Chongqing Genrix Biopharmaceutical Co ROA % Calculation

Chongqing Genrix Biopharmaceutical Co's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-801.319/( (962.107+3594.597)/ 2 )
=-801.319/2278.352
=-35.17 %

Chongqing Genrix Biopharmaceutical Co's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-737.644/( (3306.778+3280.36)/ 2 )
=-737.644/3293.569
=-22.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-737.644/3293.569
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-737.644 / 49.9)*(49.9 / 3293.569)
=Net Margin %*Asset Turnover
=-1478.24 %*0.0152
=-22.40 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Chongqing Genrix Biopharmaceutical Co ROA % Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines